Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

NCT07027072 is registered in ClinicalTrials.gov with NeuroBiogen Co., Ltd as lead sponsor.

NCT NCT07027072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07027072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease
Lead sponsor
NeuroBiogen Co., Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
August 6, 2025
Completion date
December 31, 2027
Enrollment
114 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, mild cognitive impairment (mci), mild dementia